NORTHWEST BIOTHERAPEUTICS INC (NWBO): debt financing — NW Biotherapeutics enters $5.5M loan agreement with Streeterville Capital

NORTHWEST BIOTHERAPEUTICS INC

Loan amount $5,505,000; maturity 22 months; interest 8% p.a.; 10% original issue discount.
No payments for first 8 months; 14 equal monthly installments start June 2026 at 110% pro rata principal plus interest.
Prepayment allowed with 10% charge; funds used for ongoing business operations.
Loan includes customary default provisions and potential acceleration.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

NORTHWEST BIOTHERAPEUTICS INC incurred loan of $5,505,000 with Streeterville Capital, LLC at 8% per annum maturing 22 months.

Instrument: loan
Principal: $5,505,000
Counterparty: Streeterville Capital, LLC
Rate: 8% per annum
Maturity: 22 months
Event: incurrence

Exact text from the filing

On October 27, 2025, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial Loan Agreement and Note (collectively, the “Loan Agreement”) with Streeterville Capital, LLC (the “Holder”) in the amount of $5,505,000.

View on SEC.gov

317 debt financings filed in the last 30 days. Browse all debt financings →

NORTHWEST BIOTHERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-25-104812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.